•• Huang J, et al. Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study. J Thorac Oncol. 2023;18(6):792–802. Study of global disease burden illustrating changing trends in mesothelioma incidence and disease burden by country and sex.

Article  PubMed  Google Scholar 

Royal College of Physicians. National Mesothelioma Audit report 2020 (for the audit period 2016–18). London: RCP; 2020.

Google Scholar 

Vogelzang NJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.

Article  CAS  PubMed  Google Scholar 

WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Thoracic Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2021.

Google Scholar 

Nicholson AG, et al. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020;15(1):29–49.

Article  CAS  PubMed  Google Scholar 

Mastromarino MG, Lenzini A, Aprile V, Alì G, Bacchin D, Korasidis S, Ambrogi MC, Lucchi M. New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications. Diagnostics (Basel). 2022;12(12):2905.

Article  CAS  PubMed  Google Scholar 

Forest F, et al. Histopathological typing in diffuse malignant epithelioid mesothelioma: implication for prognosis and molecular basis. Pathology. 2021;53(6):728–34.

Article  CAS  PubMed  Google Scholar 

•• Sauter JL, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022;17(5):608–22. Concise summary of major changes in 2021 WHO classification of thoracic tumours compared with 2015, outlining changes in pathological classification of pleural tumours and introduction of prognostic histological features for epithelioid mesothelioma.

Article  PubMed  Google Scholar 

Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol. 1992;9(2):151–61.

CAS  PubMed  Google Scholar 

Churg A, et al. Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol. 2020;33(2):297–302.

Article  CAS  PubMed  Google Scholar 

Davies HE, et al. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg. 2010;38(4):472–7.

Article  PubMed  Google Scholar 

Ferguson K, et al. Results of the Meso-ORIGINS feasibility study regarding collection of matched benign-mesothelioma tissue pairs by longitudinal surveillance. BMJ Open. 2023;13(8):e067780.

Article  PubMed  PubMed Central  Google Scholar 

Ferguson K, B.K., Neilson M,. S15 Evolution of mesothelioma following initial biopsies showing benign pleural inflammation, a meta-analysis. Thorax. 2021;76:A14.

Google Scholar 

• Bibby AC, et al. The priorities of people with mesothelioma and their carers: A qualitative interview study of trial participation and treatment decisions. Eur J Oncol Nurs. 2022;57:102111. Qualitative study providing important insight into the experiences of patients with mesothelioma and their carers, highlighting their key concerns as well as exploring their attitudes to being involved in clinical trials.

Article  PubMed  Google Scholar 

Neilly M, et al. An update regarding the Meso-ORIGINS study: part of the PREDICT-Meso International Accelerator. Eur Respir J. 2023;62(suppl 67):PA3434.

Google Scholar 

Kadota K, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25(2):260–71.

Article  CAS  PubMed  Google Scholar 

Zhang YZ, et al. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases. Am J Surg Pathol. 2020;44(3):347–56.

Article  PubMed  Google Scholar 

Pelosi G, et al. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. J Thorac Oncol. 2018;13(11):1750–61.

Article  PubMed  Google Scholar 

Boussios S, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018;31(6):659–69.

PubMed  PubMed Central  Google Scholar 

Lynch GA, Morley ZY, Brown A, Tucker E, Stadon L, White P, Bhatt N, Nicholson AG, Bibby AC, Maskell NA. Exploring the clinical and pathological features associated with long survival in pleural mesothelioma (PM) patients. in International Mesothelioma Interest Group. 2023. Lille. https://imig2023.org/wp-content/uploads/2023/06/WEB_PROG_IMIG.pdf

Brims FJ, et al. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. J Thorac Oncol. 2016;11(4):573–82.

Article  PubMed  Google Scholar 

Woolhouse I, et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1):e000266.

Article  PubMed  PubMed Central  Google Scholar 

Mei F, et al. Diagnostic Yield and Safety of Image-Guided Pleural Biopsy: A Systematic Review and Meta-Analysis. Respiration. 2021;100(1):77–87.

Article  PubMed  Google Scholar 

Porcel JM, et al. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147(2):502–12.

Article  PubMed  Google Scholar 

de Fonseka D, et al. Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial). BMJ Open Respir Res. 2018;5(1):e000270.

Article  PubMed  PubMed Central  Google Scholar 

De Fonseka D, et al. PET-CT-guided versus CT-guided biopsy in suspected malignant pleural thickening: a randomised trial. Eur Respir J. 2024;63(2):2301295.

Article  PubMed  PubMed Central  Google Scholar 

Agarwal PP, et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. Radiology. 2006;241(2):589–94.

Article  PubMed  Google Scholar 

Bayman N, et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. J Clin Oncol. 2019;37(14):1200–8.

Article  CAS  PubMed  Google Scholar 

Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754–8.

Article  CAS  PubMed  Google Scholar 

Clive AO, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094–104.

Article  PubMed  PubMed Central  Google Scholar 

Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6).

Dipper A, Maskell N, Bibby A. Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma. Cancers (Basel). 2021;13(13):3291.

Article  CAS  PubMed  Google Scholar 

Testa JR, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carbone M, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402–29.

Article  PubMed  PubMed Central  Google Scholar 

Hida T, et al. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer. 2017;104:98–105.

Article  PubMed  Google Scholar 

• Louw A, et al. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology. Cytopathology. 2022;33(1):84–92. Study of 50 patients with atypical cytology pleural effusion showing the increase in diagnostic accuracy in this group by the additional of BAP1 staining to the initial testing panel.

Article  PubMed  Google Scholar 

Chevrier M, et al. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathol. 2020;128(12):939–47.

Article  CAS  PubMed  Google Scholar 

Ali G, et al. A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. Oncol Lett. 2020;19(1):1060–5.

CAS  PubMed  Google Scholar 

Chapel DB, et al. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol. 2020;33(2):245–54.

Article  CAS  PubMed  Google Scholar 

Churg A, et al. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. Lung Cancer. 2018;124:95–101.

Article  PubMed  Google Scholar 

Scherpereel A, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173(10):1155–60.

Article  CAS  PubMed  Google Scholar 

Arnold DT, et al. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer. 2017;116(6):731–41.

Article  PubMed  PubMed Central